Publications by authors named "Jan Vydra"

Claim this Profile
I
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.
Agnieszka Piekarska, Mouad Abouqateb, William Boreland, Christophe Peczynski, Jan Maciej Zaucha, Jan Vydra

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT.
Jan Vydra, Allain-Thibeault Ferhat, Nicolaus Kröger, Tobias Gedde-Dahl, Matthias Eder

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.
Avichai Shimoni, Christophe Peczynski, Myriam Labopin, Alida Dominietto, Mariya Koc, Jan Vydra

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT.
Ivan Moiseev, Mouad Abouqateb, Christophe Peczynski, Alessandro Busca, Nicolaus Kröger, Jan Vydra

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.
Antoine Capes, Jarl E Mooyaart, Didier Blaise, Stefania Bramanti, Mi Kwon, Jan Vydra

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant cyclophosphamide results in lower incidence of extensive chronic graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in complete remission: a matched-pair analysis on behalf of the Acute Leukemia Working Party of the EBMT.
Giorgia Battipaglia, Myriam Labopin, Aleksandr Kulagin, Jurgen Versluis, Goda Choi, Jan Vydra

Bone Marrow Transplant· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT.
Juan Montoro, Dirk-Jan Eikema, Brian Piepenbroek, Joe Tuffnell, Khalid Halahleh, Jan Vydra

Bone Marrow Transplant· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A peripherally inserted central catheter offers a secure and reliable method of venous access for patients newly diagnosed with acute promyelocytic leukaemia.
Szotkowski Tomáš, Čerňan Martin, Sopko Ladislav, Hrabovský Štěpán, Procházka Tomáš, Vydra Jan

J Vasc Access· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Jaime Sanz, Allain-Thibeault Ferhat, Alexander Kulagin, Nicolaus Kröger, Montserrat Rovira, Jan Vydra

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis.
Juan Carlos Hernández-Boluda, Adrián Mosquera-Orgueira, Luuk Gras, Linda Koster, Joe Tuffnell, Jan Vydra

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-β Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment.
Veronika Švubová, Lucie Janstová, Marek Jedlička, Eva Mašínová, Jana Szabová, Jan Vydra

Immunotargets Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT.
Simona Pagliuca, Florent Malard, Jarl E Mooyaart, Michael Daskalakis, Ludovic Gabellier, Jan Vydra

Blood Rev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide.
Alexandros Spyridonidis, Myriam Labopin, Bipin P Savani, Alexander Kulagin, Didier Blaise, Jan Vydra

Bone Marrow Transplant· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT.
Jaime Sanz, Myriam Labopin, Jurjen Versluis, Didier Blaise, Lorenzo Lazzari, Jan Vydra

Bone Marrow Transplant· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis.
Markéta Šťastná-Marková, Pavla Pecherková, Šárka Němečková, Jitka Kryštofová, Šárka Vaníková, Jan Vydra

Transpl Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.
Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra

Immunotherapy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.
Piera Angelillo, Ana Alarcon Tomas, Edoardo Campodonico, Urban Novak, Ludovic Gabellier, Jan Vydra

Bone Marrow Transplant· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.
Avichai Shimoni, Christophe Peczynski, Myriam Labopin, Alexander Kulagin, Ellen Meijer, Jan Vydra

Leukemia· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Frédéric Baron, Myriam Labopin, Jurjen Versluis, Jan Vydra, Peter A von dem Borne

Am J Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Didier Blaise, Emanuele Angelucci, Jan Vydra

Bone Marrow Transplant· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT.
Arnon Nagler, Myriam Labopin, Urpu Salmenniemi, Depei Wu, Didier Blaise, Jan Vydra

Bone Marrow Transplant· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
Simona Piemontese, Myriam Labopin, Goda Choi, Annoek E C Broers, Jacopo Peccatori, Jan Vydra

Leukemia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Jan Vydra

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
Martin Mucha, Martin Štach, Iva Kaštánková, Jana Rychlá, Jan Vydra

Front Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
Martin Mucha, Martin Štach, Iva Kaštánková, Jana Rychlá, Jan Vydra

Front Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis